Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB ) announced today that m

With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall S

Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price

Genmab A/S (GMAB) Q2 2026 Earnings Call Transcript

Genmab (NASDAQ:GMAB) raises FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.325 billio

Genmab A/S NASDAQ: GMAB reported first-half 2026 revenue growth of 25% year over year and raised its

Avidity Partners Management LP reduced its stake in Genmab A/S Sponsored ADR (NASDAQ: GMAB) by 45.7%

Genmab's buy rating with a $36 12-month target implies roughly 25% upside from the $28.74 reference

COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NY

TD Cowen analyst Yaron Werber upgrades Genmab (NASDAQ:GMAB) from Hold to Buy and raises the price

Genmab has underperformed so far this year despite strong commercial performance and largely positiv

Wall Street lit up Tuesday with massive earnings beats and a crypto surge, but Wednesday morning fut

 Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world.

Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million

AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, back

Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY (epcoritamab) plus lenalidomide and rituxima

TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Co

Wall Street analysts updated ratings and price targets for top companies, including Robinhood, Westl

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and

Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 tria

Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label

AVAV: 31% | AeroVironment shares are trading higher after the company reported better-than-expected

The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met th

Topline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide

Company Announcement Topline results from Phase 3 EPCORE ®  DLBCL-4 evaluating epcoritamab in combin

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and

Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase it

Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act t

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 202

Results from the Phase 2 EPCORE DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrat

[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcorita

Genmab A/S (NASDAQ:GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal

Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street ana

ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse ev

Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act t

Genmab (NASDAQ:GMAB) affirms FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.065 billi

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and

Net sales of DARZALEX in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royaltie

Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab

Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-

Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrade

Wolfe Research analyst Kalpit Patel initiates coverage on Genmab (NASDAQ:GMAB) with a Outperform

Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Genmab (NASDAQ:GMAB) with a Overweig

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and

Genmab (NASDAQ:GMAB) reported quarterly earnings of $0.05 per share which missed the analyst consens